Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T

Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Steffi Teichert; Johanna Zörgiebel; Hans Jürgen Wester; Sophie M. Schneefeld; Almut C.A. Walte; James T. Thackeray; Tobias L. Ross; Frank M. Bengel

doi:10.1007/s11307-018-1160-8

Imaging Characteristics and First Experience of [⁶⁸Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [⁶⁸Ga]PSMA I&T

Thorsten Derlin
, Sebastian Schmuck
, Cathleen Juhl
, Steffi Teichert
, Johanna Zörgiebel
, Hans Jürgen Wester
, Sophie M. Schneefeld
, Almut C.A. Walte
, James T. Thackeray
, Tobias L. Ross
, Frank M. Bengel

Associate Professorship of Pharmaceutical Radiochemistry

Hannover Medical School
ROTOP Pharmaka GmbH

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Purpose: [⁶⁸Ga]Trishydroxypyridinone (THP)–prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [⁶⁸Ga]THP-PSMA. Procedures: [⁶⁸Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer. Urinary and biliary excretion and tumor lesion uptake were quantified using standardized uptake values (SUVs). Imaging characteristics were assessed in terms of non-target organ uptake, background activity, target-to-background ratios (TBRs) of tumor lesions, and frequency of bladder halo artifacts. Findings were compared to a matched cohort of 25 patients undergoing PET/CT with the established agent [⁶⁸Ga]PSMA I&T. Results: Physiologic uptake of [⁶⁸Ga]THP-PSMA was significantly lower in salivary glands (P < 0.0001), liver (P < 0.0001), spleen (P < 0.0001), and kidneys (P < 0.0001) than with [⁶⁸Ga]PSMA I&T. While biliary tracer excretion of [⁶⁸Ga]THP-PSMA was negligible, urinary tracer excretion of [⁶⁸Ga]THP-PSMA was fast, and significantly higher than for [⁶⁸Ga]PSMA I&T, contributing to a higher frequency of bladder artifacts. Malignant lesion uptake of [⁶⁸Ga]THP-PSMA assessed as either SUV or TBR was significantly lower than with [⁶⁸Ga]PSMA I&T. Conclusion: [⁶⁸Ga]THP-PSMA yields suitable in vivo uptake characteristics. The simplified synthesis method for [⁶⁸Ga]THP-PSMA may facilitate wider application and higher patient throughput with PSMA imaging. However, direct intraindividual comparison studies are needed to assess the relative performance of [⁶⁸Ga]THP-PSMA vs other PSMA ligands in terms of clinical detection rate and image quality.

Original language	English
Pages (from-to)	650-658
Number of pages	9
Journal	Molecular Imaging and Biology
Volume	20
Issue number	4
DOIs	https://doi.org/10.1007/s11307-018-1160-8
State	Published - 1 Aug 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biodistribution
PET
Physiologic
THP
[Ga]THP-PSMA

Access to Document

10.1007/s11307-018-1160-8

Cite this

Derlin, T., Schmuck, S., Juhl, C., Teichert, S., Zörgiebel, J., Wester, H. J., Schneefeld, S. M., Walte, A. C. A., Thackeray, J. T., Ross, T. L., & Bengel, F. M. (2018). Imaging Characteristics and First Experience of [⁶⁸Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [⁶⁸Ga]PSMA I&T. Molecular Imaging and Biology, 20(4), 650-658. https://doi.org/10.1007/s11307-018-1160-8

@article{7a486427b94f46e5885b1553445606f4,

title = "Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I\&T",

abstract = "Purpose: [68Ga]Trishydroxypyridinone (THP)–prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [68Ga]THP-PSMA. Procedures: [68Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer. Urinary and biliary excretion and tumor lesion uptake were quantified using standardized uptake values (SUVs). Imaging characteristics were assessed in terms of non-target organ uptake, background activity, target-to-background ratios (TBRs) of tumor lesions, and frequency of bladder halo artifacts. Findings were compared to a matched cohort of 25 patients undergoing PET/CT with the established agent [68Ga]PSMA I\&T. Results: Physiologic uptake of [68Ga]THP-PSMA was significantly lower in salivary glands (P < 0.0001), liver (P < 0.0001), spleen (P < 0.0001), and kidneys (P < 0.0001) than with [68Ga]PSMA I\&T. While biliary tracer excretion of [68Ga]THP-PSMA was negligible, urinary tracer excretion of [68Ga]THP-PSMA was fast, and significantly higher than for [68Ga]PSMA I\&T, contributing to a higher frequency of bladder artifacts. Malignant lesion uptake of [68Ga]THP-PSMA assessed as either SUV or TBR was significantly lower than with [68Ga]PSMA I\&T. Conclusion: [68Ga]THP-PSMA yields suitable in vivo uptake characteristics. The simplified synthesis method for [68Ga]THP-PSMA may facilitate wider application and higher patient throughput with PSMA imaging. However, direct intraindividual comparison studies are needed to assess the relative performance of [68Ga]THP-PSMA vs other PSMA ligands in terms of clinical detection rate and image quality.",

keywords = "Biodistribution, PET, Physiologic, THP, [Ga]THP-PSMA",

author = "Thorsten Derlin and Sebastian Schmuck and Cathleen Juhl and Steffi Teichert and Johanna Z{\"o}rgiebel and Wester, \{Hans J{\"u}rgen\} and Schneefeld, \{Sophie M.\} and Walte, \{Almut C.A.\} and Thackeray, \{James T.\} and Ross, \{Tobias L.\} and Bengel, \{Frank M.\}",

note = "Publisher Copyright: {\textcopyright} 2018, World Molecular Imaging Society.",

year = "2018",

month = aug,

day = "1",

doi = "10.1007/s11307-018-1160-8",

language = "English",

volume = "20",

pages = "650--658",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

Derlin, T, Schmuck, S, Juhl, C, Teichert, S, Zörgiebel, J, Wester, HJ, Schneefeld, SM, Walte, ACA, Thackeray, JT, Ross, TL & Bengel, FM 2018, 'Imaging Characteristics and First Experience of [⁶⁸Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [⁶⁸Ga]PSMA I&T', Molecular Imaging and Biology, vol. 20, no. 4, pp. 650-658. https://doi.org/10.1007/s11307-018-1160-8

Imaging Characteristics and First Experience of [⁶⁸Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [⁶⁸Ga]PSMA I&T. / Derlin, Thorsten; Schmuck, Sebastian; Juhl, Cathleen et al.
In: Molecular Imaging and Biology, Vol. 20, No. 4, 01.08.2018, p. 650-658.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging

T2 - Comparative Analysis with [68Ga]PSMA I&T

AU - Derlin, Thorsten

AU - Schmuck, Sebastian

AU - Juhl, Cathleen

AU - Teichert, Steffi

AU - Zörgiebel, Johanna

AU - Wester, Hans Jürgen

AU - Schneefeld, Sophie M.

AU - Walte, Almut C.A.

AU - Thackeray, James T.

AU - Ross, Tobias L.

AU - Bengel, Frank M.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: [68Ga]Trishydroxypyridinone (THP)–prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [68Ga]THP-PSMA. Procedures: [68Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer. Urinary and biliary excretion and tumor lesion uptake were quantified using standardized uptake values (SUVs). Imaging characteristics were assessed in terms of non-target organ uptake, background activity, target-to-background ratios (TBRs) of tumor lesions, and frequency of bladder halo artifacts. Findings were compared to a matched cohort of 25 patients undergoing PET/CT with the established agent [68Ga]PSMA I&T. Results: Physiologic uptake of [68Ga]THP-PSMA was significantly lower in salivary glands (P < 0.0001), liver (P < 0.0001), spleen (P < 0.0001), and kidneys (P < 0.0001) than with [68Ga]PSMA I&T. While biliary tracer excretion of [68Ga]THP-PSMA was negligible, urinary tracer excretion of [68Ga]THP-PSMA was fast, and significantly higher than for [68Ga]PSMA I&T, contributing to a higher frequency of bladder artifacts. Malignant lesion uptake of [68Ga]THP-PSMA assessed as either SUV or TBR was significantly lower than with [68Ga]PSMA I&T. Conclusion: [68Ga]THP-PSMA yields suitable in vivo uptake characteristics. The simplified synthesis method for [68Ga]THP-PSMA may facilitate wider application and higher patient throughput with PSMA imaging. However, direct intraindividual comparison studies are needed to assess the relative performance of [68Ga]THP-PSMA vs other PSMA ligands in terms of clinical detection rate and image quality.

AB - Purpose: [68Ga]Trishydroxypyridinone (THP)–prostate-specific membrane antigen (PSMA) is a novel tracer that can be labeled in one step by cold reconstitution of a kit with unprocessed generator eluate, targeting PSMA via the lysine-urea-glutamate (KuE) motif. The aim of this study was to evaluate the human imaging characteristics of [68Ga]THP-PSMA. Procedures: [68Ga]THP-PSMA positron emission tomography (PET)/x-ray computed tomography (CT) was performed in 25 patients with biochemical recurrence after radical prostatectomy for prostate cancer. Urinary and biliary excretion and tumor lesion uptake were quantified using standardized uptake values (SUVs). Imaging characteristics were assessed in terms of non-target organ uptake, background activity, target-to-background ratios (TBRs) of tumor lesions, and frequency of bladder halo artifacts. Findings were compared to a matched cohort of 25 patients undergoing PET/CT with the established agent [68Ga]PSMA I&T. Results: Physiologic uptake of [68Ga]THP-PSMA was significantly lower in salivary glands (P < 0.0001), liver (P < 0.0001), spleen (P < 0.0001), and kidneys (P < 0.0001) than with [68Ga]PSMA I&T. While biliary tracer excretion of [68Ga]THP-PSMA was negligible, urinary tracer excretion of [68Ga]THP-PSMA was fast, and significantly higher than for [68Ga]PSMA I&T, contributing to a higher frequency of bladder artifacts. Malignant lesion uptake of [68Ga]THP-PSMA assessed as either SUV or TBR was significantly lower than with [68Ga]PSMA I&T. Conclusion: [68Ga]THP-PSMA yields suitable in vivo uptake characteristics. The simplified synthesis method for [68Ga]THP-PSMA may facilitate wider application and higher patient throughput with PSMA imaging. However, direct intraindividual comparison studies are needed to assess the relative performance of [68Ga]THP-PSMA vs other PSMA ligands in terms of clinical detection rate and image quality.

KW - Biodistribution

KW - PET

KW - Physiologic

KW - THP

KW - [Ga]THP-PSMA

UR - https://www.scopus.com/pages/publications/85040679276

U2 - 10.1007/s11307-018-1160-8

DO - 10.1007/s11307-018-1160-8

M3 - Article

C2 - 29344901

AN - SCOPUS:85040679276

SN - 1536-1632

VL - 20

SP - 650

EP - 658

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 4

ER -